This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
After injecting moderate doses of the dissociative anesthetic into the animals, previously “awake” brain cells go dark, and those that had been dormant suddenly light up.
Thanks to continued weekly medications, a 16-month-old girl shows no symptoms of a severe genetic disease that typically kills children before they turn two.
Label-free techniques for analyzing biomolecular interactions offer numerous advantages for studying biological mechanisms and developing new therapeutics.
The Scientist’s Creative Services Team | 2 min read
Clive Svendsen, Meritxell Huch, Ameen Salahudeen, and Maksim Plikus will discuss the latest advances in using patient-derived stem cells to create more accurate disease models.
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
Researchers overseeing the clinical trial for the first FDA-approved oral contraceptive claimed the drug gave the Puerto Rican participants power over their family planning. Critics claimed the women were exploited.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.